Back to News
Market Impact: 0.2
Avilar Therapeutics Names Leslie Meltzer, Ph.D. as Chief Executive Officer
Source: Business Wire
Healthcare & BiotechManagement & Governance
Avilar Therapeutics named Leslie Meltzer, Ph.D., as CEO as it advances its lead sFlt1-targeting degrader toward clinical development for preeclampsia. The headline provides no timing, trial details, or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Why did Mattel stock surge 5% today?
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Nvidia's $20 billion Groq deal faces lawsuit alleging startup's stockholders were shortchanged
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Why is NeoGenomics stock sliding today?
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace